Anticipated to Monday 15 April:
Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET
Updated registration link below
NOVATO, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the conference call to discuss new clinical efficacy and safety data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome that will be presented at the American Academy of Neurology Meeting (AAN), will now be taking place on Monday, April 15, 2024 at 8 a.m. Eastern Time (ET). The slides accompanying the call will be shared on company’s website at https://ir.ultragenyx.com/events-presentations before the call.
https://ir.ultragenyx.com/news-rele...ces-update-conference-call-timing-discuss-new
Anticipated to Monday 15 April: Conference call now scheduled...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.34 |
Change
0.320(1.68%) |
Mkt cap ! $2.469B | |||
| Open | High | Low | Value | Volume |
| $19.20 | $19.41 | $18.55 | $13.89M | 728.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 624 | $19.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.35 | 6719 | 2 |
View Market Depth
| Last trade - 16.10pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.40 |
Change
0.320 ( 1.70 %) |
||||
| Open | High | Low | Volume | ||
| $19.12 | $19.40 | $18.55 | 139309 | ||
| Last updated 15.59pm 05/06/2024 ? | |||||
| NEU (ASX) Chart |